A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tao OUYANG
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female patients between 18 and 65 years old
patients with metastatic breast cancer previousely treated with A/T
able and willing to give consent to participate in the study
You may not be if
pregnant or lactating females
other tumor history
instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection
concurrent disease or condition that would make the patient inappropriate for study participation
resist to participate in the study
Clareo Health | A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
